Work

Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.591

Authors: Douglas Yee, Rebecca Arielle Shatsky, Christina Yau, Denise M. Wolf, Rita Nanda, Laura van 't Veer, Donald A. Berry, Angela DeMichele, Laura Esserman

Institutions: University of Minnesota, Masonic Cancer Center, UC San Diego Health System, University of California San Diego, University of California, San Francisco, University of Chicago Medical Center, Berry Consultants, LLC (United States), Abramson Cancer Center, University of Pennsylvania, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4281787843

Cites:

Cited by: 5

Related to: 10